Stockscreener 앱 받기
1.13
13.08%
-0.17
전일 마감가:
$1.30
열려 있는:
$1.25
하루 거래량:
6.81M
Relative Volume:
0.38
시가총액:
$81.90M
수익:
순이익/손실:
$-33.36M
주가수익비율:
-1.6851
EPS:
-0.6706
순현금흐름:
$-23.09M
1주 성능:
-18.12%
1개월 성능:
+14.07%
6개월 성능:
-11.72%
1년 성능:
+19.50%
1일 변동 폭
$1.0904
$1.26
1주일 범위
$1.0904
$1.79
52주 변동 폭
$0.1952
$1.79
Pds Biotechnology Corp Stock (PDSB) Company Profile
명칭
Pds Biotechnology Corp
전화
800-208-3343
주소
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
1.13 | 81.90M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-01 | 개시 | B. Riley Securities | Buy |
| 2021-06-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 개시 | Alliance Global Partners | Buy |
| 2020-03-09 | 개시 | Noble Capital Markets | Outperform |
| 2019-10-24 | 개시 | Chardan Capital Markets | Buy |
모두보기
Pds Biotechnology Corp 주식(PDSB)의 최신 뉴스
Form S-3 PDS Biotechnology Corp For: 14 October By Investing.com - Investing.com Nigeria
Form S-3 PDS Biotechnology Corp For: 14 October By Investing.com - Investing.com India
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? - Zacks Investment Research
PDSB Jumps As PDS Biotechnology’s Phase 2 Data Impress And Nant Deal Reshapes Outlook - Timothy Sykes
PDS Biotechnology (NasdaqCM:PDSB) Stock Forecast & Analyst Predictions - Simply Wall Street
PDSB Stock Holds Gains As Volatile Surge Attracts Momentum Traders - StocksToTrade
A National Cancer Institute investigator will discuss an experimental treatment for colorectal cancer that spread to the liver. - Stock Titan
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
PDS Biotechnology gets 19.9% Nant Capital stake | PDSB SEC FilingForm SCHEDULE 13D - Stock Titan
Patrick Soon-Shiong backs PDS Biotechnology (NASDAQ: PDSB) as cancer drugs move toward Phase 3 - stocktitan.net
PDS Biotechnology Closes $11.3 Million Initial PIPE Tranche Led by Nant Capital - Minichart
PDS Biotechnology closes $11.3M private placement led by Soon-Shiong - Investing.com India
PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board - Quiver Quantitative
PDS Biotech Raises $11.3 Million in Initial PIPE Led by Patrick Soon-Shiong - citybiz
Patrick Soon-Shiong joins PDS Biotechnology (PDSB) board in up to $22M PIPE deal - Stock Titan
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors - Investing News Network
PDS Biotechnology closes $11.3M private placement led by Soon-Shiong - Investing.com
A cancer biotech raises $11.3 million. The Los Angeles Times owner joins its board. - stocktitan.net
PDS Biotechnology Market Sentiment - Benzinga España
PDSB Stock Jumps 36% on $22.55 Million PIPE—What the Dilution Math Says - TechStock²
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
Curious about the most active stocks on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure - Quiver Quantitative
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC - AllSci
PDS Biotech soars as it announces up to $22.55 million financing - The Pharma Letter
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - Benzinga
PDS Biotechnology Announces PIPE Financing and Strategic Alignment - TipRanks
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com Canada
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com India
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com
Phase 3 trial plan could unlock $11M more for PDS Biotechnology (NASDAQ: PDSB) - Stock Titan
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks - marketscreener.com
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
PDS Biotechnology Raises $22.6 Million in Equity Funding; Shares Rise - Yahoo Finance
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com UK
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDSB News | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology Corporation Approves Workforce Reduction - marketscreener.com
PDS Biotechnology (PDSB) to shed 36% of staff and part ways with COO - stocktitan.net
Park-Ohio (PKOH) insider still holds 870K shares after gift - Stock Titan
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com India
Pds Biotechnology Corp (PDSB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):